Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
Michael Bishop(Peter MacCallum Cancer Centre), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Giovanna Andreola(European Institute of Oncology), Steven Le Gouill(Inserm), Yok‐Lam Kwong(Queen Mary Hospital), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Koji Kato(AbbVie (United States)), Catherine Thiéblemont(Université Paris Cité), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Marie José Kersten(Hovon), Richard Greil(Paracelsus Medical University), Pere Barba(Universitat Autònoma de Barcelona), Martin Dreyling(LMU Klinikum), Monique C. Minnema(University Medical Center Utrecht), Franck Morschhauser(Hôpital Claude Huriez), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joseph P. McGuirk(University of Kansas Medical Center), Evgeny Degtyarev(Universitat Autònoma de Barcelona), Emmanuel Bachy(Université Claude Bernard Lyon 1), Aisha Masood(Novartis (United States)), Martin Janz(Max Delbrück Center), Werner Rabitsch(Medical University of Vienna), Peter Borchmann(University of Cologne), Duncan Purtill(Fiona Stanley Hospital), Charalambos Andreadis(University of California, San Francisco), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Esther Hian Li Chan(Universitat Autònoma de Barcelona), Stephen J. Schuster(Hospital of the University of Pennsylvania), Nada Hamad(UNSW Sydney), Hideo Harigae(Tohoku University Hospital), Richard T. Maziarz(Oregon Health & Science University), Harald Holte(Oslo University Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Michael Dickinson(The University of Melbourne), Antonia MS Mueller(University Hospital Zurich), Peter A. McSweeney(Mesoblast (United States)), Chris del Corral, Ian W. Flinn(Tennessee Oncology), Ulrich Jaeger(Medical University of Vienna), Simon Newsome(Novartis (United Kingdom))
Cited by 15
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k